Risk assessment of hepatocellular carcinoma using transient elastography Vs. liver biopsy in chronic hepatitis b patients receiving antiviral therapy

Yeon Seok Seo, Mi Na Kim, Seung Up Kim, Sang Gyune Kim, Soon Ho Um, Kwang Hyub Han, Young Seok Kim

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Liver stiffness (LS) assessed using transient elastography (TE) can assess the risk of developing hepatocellular carcinoma (HCC). We evaluated whether TE, when compared with histological data as a reference standard, can predict the risk of HCC development in chronic hepatitis B (CHB) patients starting antiviral therapy. Observational cohort database of 381 patients with CHB who underwent liver biopsy (LB) and TE were reviewed. All patients underwent surveillance for HCC development using ultrasonography and alpha-fetoprotein. During the median follow-up period of 48.1 (interquartile range 30.3-69.3) months, HCC developed in 34 (8.9%) patients. In patients with HCC development, age, proportion of diabetes mellitus, histological fibrosis stage, and LS value were significantly higher than those in patients without (all P<0.05). The cumulative incidence rates of HCC increased significantly in association with elevated LS value in 3 stratified groups (LS value <8, 8-13, and >13 kPa; log-rank test, P<0.001), and with higher histological fibrosis stage in 3 stratified groups (F0-2, F3, and F4; log-rank test, P<0.001). On multivariate analysis, along with age, LS value was an independent predictor of HCC development (hazard ratio 1.041, P<0.001), whereas histological staging was not (P>0.05). TE predicted HCC development independently in patients with CHB starting antiviral therapy. However, further investigation is needed to determine whether the current surveillance strategy can be optimized based on the LS value at the time of starting antiviral therapy.

Original languageEnglish
Article numbere2985
JournalMedicine (United States)
Volume95
Issue number12
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Elasticity Imaging Techniques
Chronic Hepatitis
Antiviral Agents
Hepatocellular Carcinoma
Biopsy
Liver
Chronic Hepatitis B
Therapeutics
alpha-Fetoproteins
Liver Cirrhosis
Ultrasonography
Diabetes Mellitus
Databases

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{7d16a4ea032a4168ae823181cb3fc3aa,
title = "Risk assessment of hepatocellular carcinoma using transient elastography Vs. liver biopsy in chronic hepatitis b patients receiving antiviral therapy",
abstract = "Liver stiffness (LS) assessed using transient elastography (TE) can assess the risk of developing hepatocellular carcinoma (HCC). We evaluated whether TE, when compared with histological data as a reference standard, can predict the risk of HCC development in chronic hepatitis B (CHB) patients starting antiviral therapy. Observational cohort database of 381 patients with CHB who underwent liver biopsy (LB) and TE were reviewed. All patients underwent surveillance for HCC development using ultrasonography and alpha-fetoprotein. During the median follow-up period of 48.1 (interquartile range 30.3-69.3) months, HCC developed in 34 (8.9{\%}) patients. In patients with HCC development, age, proportion of diabetes mellitus, histological fibrosis stage, and LS value were significantly higher than those in patients without (all P<0.05). The cumulative incidence rates of HCC increased significantly in association with elevated LS value in 3 stratified groups (LS value <8, 8-13, and >13 kPa; log-rank test, P<0.001), and with higher histological fibrosis stage in 3 stratified groups (F0-2, F3, and F4; log-rank test, P<0.001). On multivariate analysis, along with age, LS value was an independent predictor of HCC development (hazard ratio 1.041, P<0.001), whereas histological staging was not (P>0.05). TE predicted HCC development independently in patients with CHB starting antiviral therapy. However, further investigation is needed to determine whether the current surveillance strategy can be optimized based on the LS value at the time of starting antiviral therapy.",
author = "Seo, {Yeon Seok} and Kim, {Mi Na} and Kim, {Seung Up} and Kim, {Sang Gyune} and Um, {Soon Ho} and Han, {Kwang Hyub} and Kim, {Young Seok}",
year = "2016",
month = "1",
day = "1",
doi = "10.1097/MD.0000000000002985",
language = "English",
volume = "95",
journal = "Medicine (United States)",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

Risk assessment of hepatocellular carcinoma using transient elastography Vs. liver biopsy in chronic hepatitis b patients receiving antiviral therapy. / Seo, Yeon Seok; Kim, Mi Na; Kim, Seung Up; Kim, Sang Gyune; Um, Soon Ho; Han, Kwang Hyub; Kim, Young Seok.

In: Medicine (United States), Vol. 95, No. 12, e2985, 01.01.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Risk assessment of hepatocellular carcinoma using transient elastography Vs. liver biopsy in chronic hepatitis b patients receiving antiviral therapy

AU - Seo, Yeon Seok

AU - Kim, Mi Na

AU - Kim, Seung Up

AU - Kim, Sang Gyune

AU - Um, Soon Ho

AU - Han, Kwang Hyub

AU - Kim, Young Seok

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Liver stiffness (LS) assessed using transient elastography (TE) can assess the risk of developing hepatocellular carcinoma (HCC). We evaluated whether TE, when compared with histological data as a reference standard, can predict the risk of HCC development in chronic hepatitis B (CHB) patients starting antiviral therapy. Observational cohort database of 381 patients with CHB who underwent liver biopsy (LB) and TE were reviewed. All patients underwent surveillance for HCC development using ultrasonography and alpha-fetoprotein. During the median follow-up period of 48.1 (interquartile range 30.3-69.3) months, HCC developed in 34 (8.9%) patients. In patients with HCC development, age, proportion of diabetes mellitus, histological fibrosis stage, and LS value were significantly higher than those in patients without (all P<0.05). The cumulative incidence rates of HCC increased significantly in association with elevated LS value in 3 stratified groups (LS value <8, 8-13, and >13 kPa; log-rank test, P<0.001), and with higher histological fibrosis stage in 3 stratified groups (F0-2, F3, and F4; log-rank test, P<0.001). On multivariate analysis, along with age, LS value was an independent predictor of HCC development (hazard ratio 1.041, P<0.001), whereas histological staging was not (P>0.05). TE predicted HCC development independently in patients with CHB starting antiviral therapy. However, further investigation is needed to determine whether the current surveillance strategy can be optimized based on the LS value at the time of starting antiviral therapy.

AB - Liver stiffness (LS) assessed using transient elastography (TE) can assess the risk of developing hepatocellular carcinoma (HCC). We evaluated whether TE, when compared with histological data as a reference standard, can predict the risk of HCC development in chronic hepatitis B (CHB) patients starting antiviral therapy. Observational cohort database of 381 patients with CHB who underwent liver biopsy (LB) and TE were reviewed. All patients underwent surveillance for HCC development using ultrasonography and alpha-fetoprotein. During the median follow-up period of 48.1 (interquartile range 30.3-69.3) months, HCC developed in 34 (8.9%) patients. In patients with HCC development, age, proportion of diabetes mellitus, histological fibrosis stage, and LS value were significantly higher than those in patients without (all P<0.05). The cumulative incidence rates of HCC increased significantly in association with elevated LS value in 3 stratified groups (LS value <8, 8-13, and >13 kPa; log-rank test, P<0.001), and with higher histological fibrosis stage in 3 stratified groups (F0-2, F3, and F4; log-rank test, P<0.001). On multivariate analysis, along with age, LS value was an independent predictor of HCC development (hazard ratio 1.041, P<0.001), whereas histological staging was not (P>0.05). TE predicted HCC development independently in patients with CHB starting antiviral therapy. However, further investigation is needed to determine whether the current surveillance strategy can be optimized based on the LS value at the time of starting antiviral therapy.

UR - http://www.scopus.com/inward/record.url?scp=84962166031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962166031&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000002985

DO - 10.1097/MD.0000000000002985

M3 - Article

C2 - 27015173

AN - SCOPUS:84962166031

VL - 95

JO - Medicine (United States)

JF - Medicine (United States)

SN - 0025-7974

IS - 12

M1 - e2985

ER -